deCODE Genetics Announces Full-year 2007 Financi...(k and optimizing measures to prevent the...)

deCODE's growing list of tests include deCODE T2(TM), for assessing

inherited risk of type 2 diabetes; deCODE AF(TM), for assessing risk of

atrial fibrillation, a common precursor of stroke; deCODE MI(TM), a

test for a major genetic risk factor for early-onset heart attack as

well as abdominal aortic and intracranial aneurysms; deCODE ProCa(TM),

which detects several significant genetic risk variants for prostate

cancer; and we have recently completed work on a test for assessing

inherited risk of a major type of glaucoma.

-- deCODEme(TM). Bringing together deCODE's leadership in human genetics

and recent advances in genotyping technology, in November 2007 deCODE

launched the first personal genome analysis service: deCODEme(TM). The

service takes advantage of deCODE's leadership in human genetics and

its whole-genome genotyping capabilities. Through deCODEme(TM),

subscribers can put themselves in the context of the latest discoveries

in genetics, learning what their own DNA says about their ancestry,

certain physical traits, as well as whether they have genetic variants

that have been associated with higher or lower than average risk of a

range of common diseases. This information is continually updated as

new discoveries are made, and is presented in the subscriber's secure

individual web page.

-- Arterial thrombosis: DG041. DG041 is deCODE's novel, first-in-class

antagonist of the EP3 receptor for prostaglandins E2, being developed

as a next-generation oral anti-platelet therapy for preventing arterial

thrombosis without increasing bleeding time. In a Phase II clinical

trial and additional clinical pharmacology studies completed in 2007,

DG041 was shown to dramatically inhibit platelet
'/>"/>